Vireo Growth (VREOF) Common Equity (2020 - 2026)
Vireo Growth (VREOF) posted Common Equity of $294.1 million for Q1 2026, down 4.33% sequentially from $307.4 million in Q4 2025, and up 482.38% YoY from $50.5 million in Q1 2025.
Vireo Growth (VREOF) Common Equity (2020 - 2026) Analysis & Trends
Vireo Growth has reported Common Equity for 7 years, with the latest figure at $294.1 million in Q1 2026.
- Quarterly Common Equity rose 482.38% year-over-year to $294.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $294.1 million (up 482.38% YoY) and the FY2025 annual result came in at $307.4 million, up 452.88% from the prior year.
- Common Equity declined to $294.1 million in Q1 2026 per VREOF's latest filing, from $307.4 million in the prior quarter.
- Over five years, Common Equity peaked at $307.4 million in Q4 2025 and troughed at -$22.6 million in Q1 2024.
- A 5-year average of $70.6 million and a median of $16.5 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity sank 991.83% in 2024, then jumped 2338.48% in 2025.
- Over 5 years, Common Equity stood at $3.4 million in 2022, then plunged by 566.27% to -$16.0 million in 2023, then surged by 446.55% to $55.6 million in 2024, then soared by 452.88% to $307.4 million in 2025, then dropped by 4.33% to $294.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $294.1 million, $307.4 million, and $246.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 442.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 294.10 Mn |
| Dec 31, 2025 | 307.40 Mn |
| Sep 30, 2025 | 246.31 Mn |
| Jun 30, 2025 | 268.58 Mn |
| Mar 31, 2025 | 50.50 Mn |
| Dec 31, 2024 | 55.60 Mn |
| Sep 30, 2024 | -11.00 Mn |
| Jun 30, 2024 | -22.56 Mn |
| Mar 31, 2024 | -22.58 Mn |
| Dec 31, 2023 | -16.04 Mn |
| Sep 30, 2023 | -12.85 Mn |
| Jun 30, 2023 | -7.92 Mn |
| Mar 31, 2023 | -2.07 Mn |
| Dec 31, 2022 | 3.44 Mn |
| Sep 30, 2022 | 16.48 Mn |
| Jun 30, 2022 | 24.00 Mn |
| Mar 31, 2022 | 29.08 Mn |
| Dec 31, 2021 | 43.01 Mn |
| Sep 30, 2021 | 53.81 Mn |
| Jun 30, 2021 | 59.77 Mn |